Cargando…
Good response to the late treatment with ataluren in a boy with Duchenne muscular dystrophy: could the previous mild course of the disease have affected the outcome?
Duchenne muscular dystrophy (DMD) is a severe, progressive X-linked recessive disorder, caused by the absence of the dystrophin protein. A resolutive therapy for DMD is not yet available. The first approved drug for DMD patients with nonsense mutations is ataluren, approved for the treatment of chil...
Autores principales: | Pasca, Ludovica, Gardani, Alice, Paoletti, Matteo, Velardo, Daniele, Berardinelli, Angela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Pacini Editore Srl
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628801/ https://www.ncbi.nlm.nih.gov/pubmed/36349184 http://dx.doi.org/10.36185/2532-1900-078 |
Ejemplares similares
-
Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy
por: Namgoong, John Hyun, et al.
Publicado: (2016) -
Treatment with Ataluren for Duchene Muscular
Dystrophy
por: Morkous, Sameh S.
Publicado: (2020) -
Early treatment with Ataluren of a 2-year-old boy with nonsense mutation Duchenne dystrophy
por: Bitetti, Ilaria, et al.
Publicado: (2021) -
Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients
por: McDonald, Craig M, et al.
Publicado: (2021) -
Language Development in Preschool Duchenne Muscular Dystrophy Boys
por: Chieffo, Daniela Pia Rosaria, et al.
Publicado: (2022)